In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures

International Journal of Antimicrobial Agents

Volumn 31, Issue 4, 2008, Pages 329-336

  Tré Hardy, Marie ^a   Vanderbist, Francis ^b   Traore, Hamidou ^b   Devleeschouwer, Michel Jean ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Laboratoires SMB SA   (Belgium)

Author keywords

Biofilm; Cystic fibrosis; Pseudomonas aeruginosa; Synergistic activity

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHITOSAN; CLARITHROMYCIN; COLISTIN; POLYLYSINE; POLYMYXIN B; PROTAMINE; TOBRAMYCIN;

ARTICLE; BACTERIAL INFECTION; BACTERIAL VIABILITY; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; DILUTION; DRUG ACTIVITY; DRUG POTENTIATION; IN VITRO STUDY; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; SPECTROPHOTOMETRY; SURVIVAL;

ANTI-BACTERIAL AGENTS; BIOFILMS; CLARITHROMYCIN; CYSTIC FIBROSIS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 40849142031     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.12.005     Document Type: Article

References (45)

1. Jaffè A. The anti-inflammatory effects of macrolides in cystic fibrosis. Jpn J Antibiot 54 Suppl. A (2001) 77-82
2. Muanprasat C., Kaewmokul S., and Chatsudthipong V. Identification of new small molecule inhibitors of cystic fibrosis transmembrane conductance regulator protein: in vitro and in vivo studies. Biol Pharm Bull 30 (2007) 502-507
3. Livraghi A., and Randell S.H. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 35 (2007) 116-129
4. Chen X., Schauder S., Potier N., Van Dorsselaer A., Pelczer I., Bassler B.L., et al. Structural identification of a bacterial quorum-sensing signal containing boron. Nature 415 (2002) 545-549
5. Rejman J., Di Gioia S., Bragonzi A., and Conese M. Pseudomonas aeruginosa infection destroys the barrier function of lung epithelium and enhances polyplex-mediated transfection. Hum Gene Ther 18 (2007) 642-652
6. Hoiby N., and Koch C. Cystic fibrosis 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 45 (1990) 881-884
7. Lenoir G. Pseudomonas aeruginosa and mucoviscidosis. Rev Pneumol Clin 51 (1995) 151-159 [in French]
8. Staab D. Cystic fibrosis-therapeutic challenge in cystic fibrosis children. Eur J Endocrinol 151 Suppl. 1 (2004) S77-S80
9. May T.B., Shinabarger D., Maharaj R., Kato J., Chu L., DeVault J.D., et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 4 (1991) 191-206
10. Geller D.E., Konstan M.W., Smith J., Noonberg S.B., and Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 42 (2007) 307-313
11. Mah T.F., Pitts B., Pellock B., Walker G.C., Stewart P.S., and O'Toole G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426 (2003) 306-310
12. Giamarellos-Bourboulis E.J., Antonopoulou A., Raftogiannis M., Koutoukas P., Tsaganos T., Tziortzioti V., et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 6 (2006) 31
13. Shinkai M., Lopez-Boado Y.S., and Rubin B.K. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59 (2007) 1096-1101
14. Kandemir O., Oztuna V., Milcan A., Bayramoglu A., Celik H.H., Bayarslan C., et al. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin Orthop Relat Res 430 (2005) 171-175
15. Abdi-Ali A., Mohammadi-Mehr M., and Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 27 (2006) 196-200
16. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., and Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37 (1999) 1771-1776
17. Kondoh K., Hashiba M., and Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol Suppl 525 (1996) 56-60
18. Nagata T., Mukae H., Kadota J., Hayashi T., Fujii T., Kuroki M., et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother 48 (2004) 2251-2259
19. Falagas M.E., and Kasiakou S.K. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection 35 (2007) 3-10
20. Hancock R.E., and Bell A. Antibiotic uptake into Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 7 (1988) 713-720
21. Nicas T.I., and Hancock R.E. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 143 (1980) 872-878
22. Mor N., and Heifets L. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother 37 (1993) 111-114
23. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard. M7-A6. Wayne, PA: CLSI; 2003.
24. Balke B., Hogardt M., Schmoldt S., Hoy L., Weissbrodt H., and Haussler S. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 25 (2006) 25-30
25. Mackay M.L., Milne K., and Gould I.M. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents 15 (2000) 125-129
26. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52 (2003) 1
27. Gordon C.A., Hodges N.A., and Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother 22 (1988) 667-674
28. Cystic Fibrosis Inhaled Tobramycin Study Group, Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340 (1999) 23-30
29. British Society for Antimicrobial Chemotherapy. Determination of minimum inhibitory concentrations. Guide to antimicrobial susceptibility testing (2006), BSAC, Birmingham, UK p. 19
30. Aaron S.D., Ferris W., Ramotar K., Vandemheen K., Chan F., and Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40 (2002) 4172-4179
31. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 99 (1995) 26S-30S
32. Rubin B.K., Druce H., Ramirez O.E., and Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 155 (1997) 2018-2023
33. Anwar H., and Costerton J.W. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34 (1990) 1666-1671
34. Eckert R., Brady K.M., Greenberg E.P., Qi F., Yarbrough D.K., He J., et al. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 50 (2006) 3833-3838
35. Tanaka G., Shigeta M., Komatsuzawa H., Sugai M., Suginaka H., and Usui T. Effect of clarithromycin on Pseudomonas aeruginosa biofilms. Chemotherapy 46 (2000) 36-42
36. Saiman L., Chen Y., Gabriel P.S., and Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46 (2002) 1105-1107
37. Yasuda H., Ajiki Y., Koga T., Kawada H., and Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 37 (1993) 1749-1755
38. Ichimiya T., Yamasaki T., and Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 34 (1994) 331-341
39. Tamaoki J., Isono K., Sakai N., Kanemura T., and Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 5 (1992) 234-238
40. Guillot M., Eckart P., Desrosieres H., and Brouard J. Macrolides and Pseudomonas aeruginosa infection. Arch Pediatr 7 Suppl. 3 (2000) 523s-530s [in French]
41. Howe R.A., and Spencer R.C. Macrolides for the treatment of Pseudomonas aeruginosa infections?. J Antimicrob Chemother 40 (1997) 153-155
42. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54 (2004) 21-28
43. Takeoka K., Ichimiya T., Yamasaki T., and Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 44 (1998) 190-197
44. Bui K.Q., Banevicius M.A., Nightingale C.H., Quintiliani R., and Nicolau D.P. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J Antimicrob Chemother 45 (2000) 57-62
45. Yanagihara K., Tomono K., Sawai T., Kuroki M., Kaneko Y., Ohno, et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother 46 (2000) 69-72